Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Clinical trial NCT05536349 · RECRUITING
Trial details
- NCT number
- NCT05536349
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-20
- Primary completion
- 2028-04-25
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.